Clinical Trials Logo

Ovary Neoplasm clinical trials

View clinical trials related to Ovary Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05292859 Active, not recruiting - Colorectal Cancer Clinical Trials

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Start date: October 1, 2022
Phase:
Study type: Observational

Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors

NCT ID: NCT05194735 Active, not recruiting - Colorectal Cancer Clinical Trials

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Start date: April 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors

NCT ID: NCT03371693 Active, not recruiting - Ovarian Cancer Clinical Trials

Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer

HIPECOV
Start date: September 30, 2017
Phase: Phase 3
Study type: Interventional

A phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC( Hyperthermic Intraperitoneal Chemotherapy). The target population for this study is patients with primary or recurrence ovarian, peritoneal or fallopian tube cancers undergoing CRS( Cytoreductive Surgery). Patients will be divided into two groups. Group A will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy. Group B will undergo CRS and then go on to intravenous chemotherapy.